BCYC News and Press, Bicycle Therapeutics plc From 03/11/21

- Significant progress achieved across pipeline of Bicycle ® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™) - Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical studies of Bicycle ...

Gainers: Datasea (DTSS) +90%.Lexicon Pharmaceuticals (LXRX) +85%.Pennsylvania Real Estate Investment Trust (PEI) +50%.DPW Holdings (DPW) +36%.Organogenesis (ORGO) +34%.Acacia Communications (ACIA) +33%.Bicycle Therapeutics (BCYC) +31%.AeroVironment (AVAV) +29%.Maxar Technologie...

Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...

Bicycle Therapeutics (BCYC) provides pipeline updates on its early and mid-stage cancer trials and announces plans to start recruitment for its first clinical site outside the United States to test its tumor antigen BT8009.The first patient was dosed in an open-label ...

Bicycle Therapeutics (BCYC) has entered into a settlement and license agreement with Pepscan Systems regarding Bicycle’s use of Pepscan’s CLIPS peptide technology.Both the companies have agreed to settle all intellectual property ((IP)) disputes worldwide, and Bicycle has been g...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the 2020...

Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that it has entered into a settlement and license agre...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Jeff...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agoni...